Trial · NCT05550532
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Placebo | -9.4 | Standard Error 0.96 | Units on a scale | |
| Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Aticaprant 10 mg | -10.0 | Standard Error 0.96 | Units on a scale | |
| Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score | Placebo | 8.2 | Standard Error 1.39 | Units on a scale | |
| Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score | Aticaprant 10 mg | 8.8 | Standard Error 1.39 | Units on a scale | |
| Change From Baseline Over Time in MADRS Total Score | Placebo | Day 15 | -4.4 | Standard Error 0.75 | Units on a scale |
| Change From Baseline Over Time in MADRS Total Score | Aticaprant 10 mg | Day 15 | -5.4 | Standard Error 0.74 | Units on a scale |
| Change From Baseline Over Time in MADRS Total Score | Placebo | Day 29 | -7.5 | Standard Error 0.89 | Units on a scale |
| Change From Baseline Over Time in MADRS Total Score | Aticaprant 10 mg | Day 29 | -8.0 | Standard Error 0.89 | Units on a scale |
| Change From Baseline Over Time in MADRS Total Score | Placebo | Day 43 | -9.4 | Standard Error 0.96 | Units on a scale |
| Change From Baseline Over Time in MADRS Total Score | Aticaprant 10 mg | Day 43 | -10.0 | Standard Error 0.96 | Units on a scale |
| Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43 | Placebo | 28.3 | Percentage of participants | ||
| Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43 | Aticaprant 10 mg | 27.9 | Percentage of participants | ||
| Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 43 | Placebo | 16.3 | Percentage of participants | ||
| Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score at Day 43 | Aticaprant 10 mg | 15.8 | Percentage of participants | ||
| Change From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score | Placebo | -5.5 | Standard Error 0.58 | Units on a scale | |
| Change From Baseline to Day 43 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score | Aticaprant 10 mg | -5.2 | Standard Error 0.58 | Units on a scale | |
| Change From Baseline Over Time in DARS Total Score | Placebo | Day 15 | 3.5 | Standard Error 1.17 | Units on a scale |
| Change From Baseline Over Time in DARS Total Score | Aticaprant 10 mg | Day 15 | 4.2 | Standard Error 1.17 | Units on a scale |
| Change From Baseline Over Time in DARS Total Score | Placebo | Day 29 | 6.9 | Standard Error 1.27 | Units on a scale |
| Change From Baseline Over Time in DARS Total Score | Aticaprant 10 mg | Day 29 | 7.1 | Standard Error 1.27 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05550532/results